瑞银发表研究报告指,诺诚健华(09969.HK) 与礼来(LLY.US) 就发现及开发最多5个创新靶点项目达成合作,该行对此持正面看法,认为属对公司研发能力的认可。该行指出,预付款及近期里程碑付款合共1亿美元,潜在研发及商业里程碑付款达32.5亿美元,并可获净销售额单位数百分比分层权利金。据管理层表示,所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利带来上行空间。该行维持诺诚健华“...
Source Link瑞银发表研究报告指,诺诚健华(09969.HK) 与礼来(LLY.US) 就发现及开发最多5个创新靶点项目达成合作,该行对此持正面看法,认为属对公司研发能力的认可。该行指出,预付款及近期里程碑付款合共1亿美元,潜在研发及商业里程碑付款达32.5亿美元,并可获净销售额单位数百分比分层权利金。据管理层表示,所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利带来上行空间。该行维持诺诚健华“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.